Request Demo
Last update 22 Dec 2025
4SCAR-PSMA(Shenzhen Geno-Immune Medical Institute)
Last update 22 Dec 2025
Overview
Basic Info
Drug Type Autologous CAR-T |
Synonyms 4SCAR PSMA, 4SCARPSMA |
Target |
Action inhibitors |
Mechanism PSMA inhibitors(Prostate-specific membrane antigen inhibitors), Gene transference(Gene transference), T lymphocyte replacements |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
6
Clinical Trials associated with 4SCAR-PSMA(Shenzhen Geno-Immune Medical Institute)NCT03185468
Intervention of Advanced or Metastatic Urothelial Bladder Cancer by 4SCAR-T Cell Therapies
NCT03050190
A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
NCT04637503
Multi-center Phase I/II Clinical Trial of 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma
100 Clinical Results associated with 4SCAR-PSMA(Shenzhen Geno-Immune Medical Institute)
Login to view more data
100 Translational Medicine associated with 4SCAR-PSMA(Shenzhen Geno-Immune Medical Institute)
Login to view more data
100 Patents (Medical) associated with 4SCAR-PSMA(Shenzhen Geno-Immune Medical Institute)
Login to view more data
100 Deals associated with 4SCAR-PSMA(Shenzhen Geno-Immune Medical Institute)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Metastatic urothelial carcinoma | Phase 2 | China | 01 Aug 2025 | |
| Urothelial Carcinoma of the Urinary Bladder | Phase 2 | China | 01 Aug 2025 | |
| Chronic Lymphocytic Leukemia | Phase 2 | China | 01 May 2025 | |
| Neuroblastoma | Phase 2 | China | 18 Nov 2020 | |
| B-cell lymphoma refractory | Phase 2 | China | 01 Jun 2020 | |
| PSMA-Positive Tumor | Phase 2 | China | 01 Jan 2020 | |
| Recurrent Cervical Cancer | Phase 2 | China | 15 Nov 2017 | |
| Bladder Cancer | Phase 2 | China | 08 May 2017 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free